TY - JOUR
T1 - A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV)
AU - Bialer, Meir
AU - Johannessen, Svein I.
AU - Koepp, Matthias J.
AU - Levy, René H.
AU - Perucca, Emilio
AU - Tomson, Torbjörn
AU - White, H. Steve
N1 - Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/7
Y1 - 2019/7
N2 - The Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV) took place in Madrid, Spain from May 13th to 16th 2018. Again, presentations on new medical devices and neuromodulation and discussions on device-related regulatory aspects were included in the programme. The virtual special issue on “neuromodulation” summarises the presentations focusing firstly, on the pre-clinical developments and the difficulties of clinical trial designs for neuromodulatory therapies, including vagus nerve stimulation (VNS) and Brain-Responsive Neurostimulation (RNS), and the use of transcutaneous vagus nerve stimulation (tVNS) as a potential screening tool for determining the efficacy of neuromodulatory treatments in individual patients; secondly, on wearable devices for seizure monitoring through indices of peripheral sympathetic nervous activity, the use of such devices in combination with biofeedback for the treatment of epilepsy, and its potential for improving epilepsy specialist services, particularly in remote areas.
AB - The Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV) took place in Madrid, Spain from May 13th to 16th 2018. Again, presentations on new medical devices and neuromodulation and discussions on device-related regulatory aspects were included in the programme. The virtual special issue on “neuromodulation” summarises the presentations focusing firstly, on the pre-clinical developments and the difficulties of clinical trial designs for neuromodulatory therapies, including vagus nerve stimulation (VNS) and Brain-Responsive Neurostimulation (RNS), and the use of transcutaneous vagus nerve stimulation (tVNS) as a potential screening tool for determining the efficacy of neuromodulatory treatments in individual patients; secondly, on wearable devices for seizure monitoring through indices of peripheral sympathetic nervous activity, the use of such devices in combination with biofeedback for the treatment of epilepsy, and its potential for improving epilepsy specialist services, particularly in remote areas.
UR - http://www.scopus.com/inward/record.url?scp=85063113192&partnerID=8YFLogxK
U2 - 10.1016/j.eplepsyres.2019.03.002
DO - 10.1016/j.eplepsyres.2019.03.002
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.editorial???
C2 - 30910314
AN - SCOPUS:85063113192
SN - 0920-1211
VL - 153
SP - 66
EP - 67
JO - Epilepsy Research
JF - Epilepsy Research
ER -